Jack Slevin
Stock Analyst at Jefferies
(3.95)
# 1,825
Out of 4,609 analysts
40
Total ratings
57.1%
Success rate
20.1%
Average return
Main Sectors:
Stocks Rated by Jack Slevin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AHCO AdaptHealth | Upgraded: Buy | $13 | $6.05 | +115.05% | 1 | Jul 21, 2026 | |
| LFST LifeStance Health Group | Maintained: Buy | $14 | $10.66 | +31.33% | 1 | Jul 16, 2026 | |
| CVSA Covista | Reiterated: Buy | $175 | $124.26 | +40.83% | 4 | Jun 30, 2026 | |
| ASTH Astrana Health | Reiterated: Buy | $37 → $53 | $34.13 | +55.29% | 9 | Jun 30, 2026 | |
| AGL agilon health | Upgraded: Buy | $28 → $48 | $86.83 | -44.72% | 8 | May 7, 2026 | |
| MD Pediatrix Medical Group | Maintained: Buy | $21 → $27 | $26.51 | +1.85% | 4 | Apr 20, 2026 | |
| USPH U.S. Physical Therapy | Rated: Buy | $102 | $76.46 | +33.40% | 1 | Mar 9, 2026 | |
| PRVA Privia Health Group | Reiterated: Buy | $30 → $32 | $22.00 | +45.45% | 6 | Feb 26, 2026 | |
| AMN AMN Healthcare Services | Maintained: Hold | $22 → $21 | $30.80 | -31.82% | 4 | Aug 13, 2025 | |
| STLN Starling Oncology | Maintained: Buy | $2.5 → $2 | $4.99 | n/a | 2 | Jun 10, 2024 |
AdaptHealth
Jul 21, 2026
Upgraded: Buy
Price Target: $13
Current: $6.05
Upside: +115.05%
LifeStance Health Group
Jul 16, 2026
Maintained: Buy
Price Target: $14
Current: $10.66
Upside: +31.33%
Covista
Jun 30, 2026
Reiterated: Buy
Price Target: $175
Current: $124.26
Upside: +40.83%
Astrana Health
Jun 30, 2026
Reiterated: Buy
Price Target: $37 → $53
Current: $34.13
Upside: +55.29%
agilon health
May 7, 2026
Upgraded: Buy
Price Target: $28 → $48
Current: $86.83
Upside: -44.72%
Pediatrix Medical Group
Apr 20, 2026
Maintained: Buy
Price Target: $21 → $27
Current: $26.51
Upside: +1.85%
U.S. Physical Therapy
Mar 9, 2026
Rated: Buy
Price Target: $102
Current: $76.46
Upside: +33.40%
Privia Health Group
Feb 26, 2026
Reiterated: Buy
Price Target: $30 → $32
Current: $22.00
Upside: +45.45%
AMN Healthcare Services
Aug 13, 2025
Maintained: Hold
Price Target: $22 → $21
Current: $30.80
Upside: -31.82%
Starling Oncology
Jun 10, 2024
Maintained: Buy
Price Target: $2.5 → $2
Current: $4.99
Upside: n/a